|
๐
|
Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma.
24 auth.
M. Dimopoulos,
A. Oriol,
H. Nahi,
J. San-Miguel,
N. Bahlis,
S. Usmani,
N. Rabin,
R. Orlowski,
M. Komarnicki,
Kenshi Suzuki,
...
T. Plesner,
S. Yoon,
D. Ben Yehuda,
P. Richardson,
H. Goldschmidt,
D. Reece,
S. Lisby,
N. Khokhar,
L. OโRourke,
Christopher Chiu,
X. Qin,
Mary E. Guckert,
T. Ahmadi,
P. Moreau
|
10 |
2016 |
10
๐
|
|
๐
|
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
26 auth.
P. Moreau,
T. Masszi,
N. Grzฤ
ลko,
N. Bahlis,
M. Hansson,
L. Pour,
I. Sandhu,
P. Ganly,
B. Baker,
S. Jackson,
A. Stoppa,
D. Simpson,
P. Gimsing,
A. Palumbo,
L. Garderet,
...
M. Cavo,
Shaji K. Kumar,
C. Touzeau,
F. Buadi,
J. Laubach,
D. Berg,
Jianchang Lin,
A. Di Bacco,
A. Hui,
H. V. D. van de Velde,
P. Richardson
|
9 |
2016 |
9
๐
|
|
๐
|
Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
32 auth.
S. Lonial,
B. Weiss,
S. Usmani,
S. Singhal,
A. Chari,
N. Bahlis,
A. Belch,
A. Krishnan,
R. Vescio,
M. Mateos,
A. Mazumder,
R. Orlowski,
H. Sutherland,
J. Bladรฉ,
E. Scott,
...
A. Oriol,
J. Berdeja,
M. Gharibo,
D. Stevens,
R. LeBlanc,
M. Sebag,
N. Callander,
A. Jakubowiak,
D. White,
J. Rubia,
P. Richardson,
S. Lisby,
Huaibao Feng,
C. Uhlar,
I. Khan,
T. Ahmadi,
P. Voorhees
|
9 |
2016 |
9
๐
|
|
๐
|
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.
34 auth.
L. Benboubker,
M. Dimopoulos,
A. Dispenzieri,
J. Catalano,
A. Belch,
M. Cavo,
A. Pinto,
K. Weisel,
H. Ludwig,
N. Bahlis,
A. Banos,
M. Tiab,
M. Delforge,
J. Cavenagh,
C. Geraldes,
...
Je-Jung Lee,
Christine I. Chen,
A. Oriol,
J. de la Rubia,
L. Qiu,
D. White,
D. Binder,
K. Anderson,
J. Fermand,
P. Moreau,
M. Attal,
R. Knight,
Guang Chen,
Jason Van Oostendorp,
C. Jacques,
A. ErvinโHaynes,
H. Avet-Loiseau,
C. Hulin,
T. Facon
|
9 |
2014 |
9
๐
|
|
๐
|
Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma.
30 auth.
T. Facon,
Shaji K. Kumar,
T. Plesner,
R. Orlowski,
P. Moreau,
N. Bahlis,
S. Basu,
H. Nahi,
C. Hulin,
H. Quach,
H. Goldschmidt,
M. O'Dwyer,
A. Perrot,
C. Venner,
K. Weisel,
...
J. Mace,
N. Raje,
M. Attal,
M. Tiab,
M. Macro,
L. Frenzel,
X. Leleu,
T. Ahmadi,
Christopher Chiu,
Jianping Wang,
Rian Van Rampelbergh,
C. Uhlar,
R. Kobos,
M. Qi,
S. Usmani
|
9 |
2019 |
9
๐
|
|
๐
|
A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma.
23 auth.
D. Siegel,
T. Martin,
Michael L. Wang,
R. Vij,
A. Jakubowiak,
S. Lonial,
S. Trudel,
V. Kukreti,
N. Bahlis,
M. Alsina,
...
A. Chanan-Khan,
F. Buadi,
F. Reu,
G. Somlo,
J. Zonder,
K. Song,
A. Stewart,
E. Stadtmauer,
L. Kunkel,
Sandra Wear,
A. Wong,
R. Orlowski,
S. Jagannath
|
9 |
2012 |
9
๐
|
|
๐
|
Teclistamab in Relapsed or Refractory Multiple Myeloma.
34 auth.
P. Moreau,
A. Garfall,
N. V. D. van de Donk,
H. Nahi,
J. San-Miguel,
A. Oriol,
A. Nooka,
T. Martin,
L. Rosiรฑol,
A. Chari,
L. Karlin,
L. Benboubker,
M. Mateos,
N. Bahlis,
R. Popat,
...
B. Besemer,
J. Martรญnez-Lรณpez,
S. Sidana,
M. Delforge,
L. Pei,
D. Trancucci,
R. Verona,
S. Girgis,
S. X. W. Lin,
Y. Olyslager,
M. Jaffe,
C. Uhlar,
T. Stephenson,
Rian Van Rampelbergh,
A. Banerjee,
J. Goldberg,
R. Kobos,
A. Krishnan,
S. Usmani
|
8 |
2022 |
8
๐
|
|
๐
|
Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma.
18 auth.
S. Usmani,
B. Weiss,
T. Plesner,
N. Bahlis,
A. Belch,
S. Lonial,
H. Lokhorst,
P. Voorhees,
P. Richardson,
A. Chari,
...
A. Sasser,
A. Axel,
Huaibao Feng,
C. Uhlar,
Jianping Wang,
I. Khan,
T. Ahmadi,
H. Nahi
|
8 |
2015 |
8
๐
|
|
๐
|
Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study.
24 auth.
P. Richardson,
D. Siegel,
R. Vij,
C. Hofmeister,
R. Baz,
S. Jagannath,
Christine I. Chen,
S. Lonial,
A. Jakubowiak,
N. Bahlis,
...
K. Song,
A. Belch,
N. Raje,
C. Shustik,
S. Lentzsch,
M. Lacy,
J. Mikhael,
J. Matous,
D. Vesole,
Min S. Chen,
M. Zaki,
C. Jacques,
Zhinuan Yu,
K. Anderson
|
8 |
2014 |
8
๐
|
|
๐ฌ
|
Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells.
J. M. Grad,
N. Bahlis,
I. M. Reis,
M. Oshiro,
W. Dalton,
L. Boise
|
8 |
2001 |
8
๐ฌ
|
|
๐
|
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
22 auth.
P. Rodrรญguez-Otero,
S. Ailawadhi,
B. Arnulf,
K. Patel,
M. Cavo,
A. Nooka,
S. Manier,
N. Callander,
L. Costa,
R. Vij,
...
N. Bahlis,
P. Moreau,
S. Solomon,
M. Delforge,
J. Berdeja,
A. Truppel-Hartmann,
Zhihong Yang,
L. FavreโKontula,
Fan Wu,
J. Piasecki,
M. Cook,
S. Giralt
|
8 |
2023 |
8
๐
|
|
๐
|
An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma.
24 auth.
R. Vij,
Michael L. Wang,
J. Kaufman,
S. Lonial,
A. Jakubowiak,
A. Stewart,
V. Kukreti,
S. Jagannath,
K. McDonagh,
M. Alsina,
...
N. Bahlis,
F. Reu,
N. Gabrail,
A. Belch,
J. Matous,
Peter P. Lee,
P. Rosen,
M. Sebag,
D. Vesole,
L. Kunkel,
Sandra Wear,
A. Wong,
R. Orlowski,
D. Siegel
|
8 |
2012 |
8
๐
|
